Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2010

View Archived Issues

VALET data show superiority of valsartan/HCTZ vs. monotherapy in elderly hypertensive patients

Lysine-specific histone demethylase 1A inhibitors claimed by Oryzon Genomics

Spirogen discloses pyrrolobenzodiazepine derivatives

Glucagon-like peptide-1 shows potential in IBS and hepatic steatosis

Shionogi transfers sales rights of Avelox to Bayer Healthcare

Boehringer Ingelheim developing novel MMP-13 inhibitors

Chroma Therapeutics researchers disclose novel HSP 90 inhibitors

Proacta develops improved prodrugs of pan-HER inhibitors

Endo signs agreement to acquire urological product provider, HealthTronics

FDA approves Cipher's CIP-Tramadol ER pain treatment

Ferring acquires global rights to Lysteda from Xanodyne

Humanized monoclonal IgG2 antibody AB-16B5 shown to directly target EMT transition

Swedish Orphan Biovitrum and Biomodels enter agreement to develop mucositis risk assay

Sanofi-aventis reports first quarter accomplishments

Novel TRPV1 antagonists described by Abbott

Scancell signs agreement with NIH for SCIB-1 melanoma vaccine components

Crucell and NIH commence malaria vaccine trial in Burkina Faso

GlaxoSmithKline discloses novel IGF-1R tyrosine kinase inhibitors

Merck & Co. highlights late-stage pipeline

Gelonin/Adnectin-IGF1R fusion construct inhibits tumor growth in vitro and in vivo

Achillion's ACH-1625 reduces hepatitis C RNA in phase Ib trial

SkyePharma provides pipeline and product update

Amorfix and Epitomics agreement to develop mAbs for treatment of cancer

Anacor Pharmaceuticals claims new agents for treating protozoal infections

PharmaGap to announce results of NCI testing of GAP-102B8 within a few days

AR antagonist BMS-779333 shows promise in prostate cancer models

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026